阵发性睡眠性血红蛋白尿症患者血小板膜补体复合物沉积及其异常活化的研究
目的 通过检测阵发性睡眠性血红蛋白尿症(PNH)伴或不伴再生障碍性贫血(AA)患者血小板膜补体复合物(C5b-9)、血小板活化分子(CD62p)表达及血清可溶性C5b-9(sC5b-9)水平探究PNH血栓形成的病理机制.方法 用ELISA方法检测25例PNH/PNH-AA患者血清sC5b-9、补体C3和C4水平,并以30名健康志愿者作为正常对照;采用流式细胞术检测PNH/PNH-AA患者与正常人血小板PNH克隆数(CD59-CD61+/CD61+)、血小板膜C5b-9沉积率(C5b-9+CD61+/CD61+)以及血小板活化标志分子CD62p表达率(CD62p+CD61+/CD61+),并进行...
Saved in:
Published in | 中华血液学杂志 Vol. 36; no. 6; pp. 515 - 519 |
---|---|
Main Author | |
Format | Journal Article |
Language | Chinese |
Published |
300052,天津医科大学总医院血液内科
2015
|
Subjects | |
Online Access | Get full text |
ISSN | 0253-2727 |
DOI | 10.3760/cma.j.issn.0253-2727.2015.06.015 |
Cover
Summary: | 目的 通过检测阵发性睡眠性血红蛋白尿症(PNH)伴或不伴再生障碍性贫血(AA)患者血小板膜补体复合物(C5b-9)、血小板活化分子(CD62p)表达及血清可溶性C5b-9(sC5b-9)水平探究PNH血栓形成的病理机制.方法 用ELISA方法检测25例PNH/PNH-AA患者血清sC5b-9、补体C3和C4水平,并以30名健康志愿者作为正常对照;采用流式细胞术检测PNH/PNH-AA患者与正常人血小板PNH克隆数(CD59-CD61+/CD61+)、血小板膜C5b-9沉积率(C5b-9+CD61+/CD61+)以及血小板活化标志分子CD62p表达率(CD62p+CD61+/CD61+),并进行相关性分析.结果 ①PNH/PNH-AA组患者血清sC5b-9水平为390.27(265.73~676.87)μg/L,显著低于正常对照组的540.39(344.20~1 576.78)tg/L(P<0.01).②PNH/PNH-AA组患者血小板PNH克隆数[50.58(23.29~81.60)%]显著高于正常对照组[23.57(15.58~29.02)%](P<0.01);PNH/PNH-AA组患者PNH克隆血小板膜C5b-9沉积率[(17.53±6.27)%]与患者正常血小板[(11.33±5.03)%]及正常对照组血小板[(10.88±3.58)%]相比均显著增高(P<0.01).③PNH/PNH-AA组患者PNH克隆血小板CD62p表达率[(61.98±11.71)%]与患者正常血小板[(43.76±11.30)%]及正常对照组血小板[(38.23±8.07)%]相比均显著升高(P<0.01);PNH/PNH-AA组患者正常血小板膜CD62p表达率比正常对照组血小板显著增高(P<0.05).④血小板膜C5b-9沉积率与CD62p表达率呈显著正相关(r=0.449,P=0.002).结论 PNH/PNH-AA患者血小板锚连蛋白(CD59)缺失导致补体复合物C5b-9沉积于异常血小板膜并使其激活,这一过程可能参与PNH血栓的形成. |
---|---|
Bibliography: | Objective To explore the expression levels of terminal complement complex (C5b-9) and CD62p on platelets and the soluble C5b-9 (sC5b-9) level in serum in patients with PNH or PNH-aplastic anemia (AA).Methods Serum levels ofsC5b-9,complement C3 and C4 were detected by using ELISA in 25 patients with PNH/PNH-AA.The quantities of C5b-9 and CD62p on the membrane of platelets were detected by flow cytometry.Results ①In PNH/PNH-AA group,the serum sC5b-9 level [390.27 (265.73-676.87) μg/L] was lower than that in control group [540.39 (344.20-1 576.78) tg/L] (P< 0.01).②The platelet PNH clone (CD59-CD61VCD61+) size [50.58 (23.29-81.60)%] was bigger in the PNH/PNH-AA group than that [23.57 (15.58-29.02)%] in control group (P<0.01).The percentages of C5b-9 deposition (C5b-9+CD61+/CD61+) were higher on the PNH clone platelets (CD59-CD61+) in the PNH/PNH-AA group [(17.53±6.27)%] than those on the normal platelets (CD59+CD61+) in PNH patients [(11.33±5.03)%] and control [(10.88±3.58)%] group (P<0.01).③The expression of CD6 |
ISSN: | 0253-2727 |
DOI: | 10.3760/cma.j.issn.0253-2727.2015.06.015 |